目的:观察派姆单抗联合安罗替尼治疗晚期食管鳞状细胞癌（ESCC）的效果。方法:回顾性分析江苏大学附属昆山医院收治的1例晚期ESCC并发生肺转移和肝转移患者的临床资料，并复习相关文献。结果:该患者为老年女性，ESCC经过治疗后出现肺转移和肝转移，予派姆单抗联合安罗替尼治疗，疗效达部分缓解，无进展生存期约9个月。结论:晚期ESCC三线治疗采用派姆单抗联合安罗替尼治疗可获得良好疗效。

目的:探讨65岁以上老年食管癌放疗病人血清白介素(IL)-37水平与放疗疗效、无进展生存期(PFS)等的相关性及其临床意义.方法:采用酶联免疫吸附实验(ELISA)法检测107例食管癌病人及107例健康对照的血清IL-37水平,分析两组之间的差异,并评估IL-37水平与食管癌分期、放疗疗效、PFS之间的相关性.结果:食管癌组与健康对照组相比,血清IL-37水平显著增高.IL-37水平与老年食管癌放疗病人的淋巴结转移、临床分期及疗效评估相关,生存分析显示高血清IL-37水平的病人放疗后PFS时间短.结论:血清IL-37水平是老年食管癌病人病情评估的重要指标,并与放疗后的预后相关.

目的 探讨每日锥形束CT(CBCT)技术在纠正宫颈癌放疗人工摆位误差中的应用价值.方法 选取接受调强放射治疗(IMRT)的宫颈癌患者18例,每日放疗前均行CBCT扫描,并与计划CT图像骨性匹配,结合手动微调,获得前后(Vrt)、头脚(Lng)、左右(Lat)三个方向的线性摆位误差,摆位误差纠正后再次CBCT扫描,分别记录每次的摆位误差并进行分析.结果 18例患者共行906次CBCT扫描,摆位误差纠正前和纠正后Vrt方向总平均值(M)、系统误差(∑)、随机误差(σ)分别为0.581、4.068、1.160 mm和0.049、0.292、0.277 mm,Lng方向纠正前后分别为0.789、3.637、2.031 mm和0.477、0.391、0.539 mm,Lat方向纠正前后分别为-0.375、2.515、1.564 mm和0.094、0.109、0.238 mm.摆位误差纠正前Vrt、Lng、Lat方向CTV-PTV外放边界(MPTV)分别为10.981、10.514、7.381 mm,摆位误差纠正后MPTV分别为0.925、1.353、0.440 mm.摆位误差纠正前和纠正后肿瘤中心点移动距离分别为(8.890±7.222) mm和(1.021±1.075) mm,CBCT纠正后摆位误差范围较纠正前显著减少(P＜0.05).结论 宫颈癌IMRT中每日行CBCT校正可明显减少摆位误差,提高放疗精确性.

Objective To observe the efficacy of kanglaite injection combined with SOX chemotherapy regimen in the treatment of advanced gastric cancer.Methods A total of 104 patients with advanced gastric cancer was randomly divided into two groups.The patients in group B were treated with SOX chemotherapy regimen,which included intravenously oxaliplatin 130mg/m2 at day 1 and orally S-1 40-60mg,bid at day 1 to 14 for 3 weeks as a cycle.The patients in group A were treated with SOX chemotherapy regimen combined with kanglaite injection 200ml intravenously,at day 1 to 10.The efficacy and adverse effects were evaluated after two cycles of chemotherapy.Results The effectiveness rate and disease control rate of groups of A and B were similar(P>0.05).Compared to group B,group A had less incidence rates of peripheral nerve toxicity(40.7% vs.62.0%),decrease of WBC(48.1% vs.68.0%),and nausea and vomiting(24.1% vs.44.0%)(P<0.05),and higher rate of improved quality of life(46.3% vs.24.0%)(P<0.05).Conclusion On the basis of SOX regimen,combined use of kanglaite injection can reduce chemotherapy-related adverse effects and improve the quality of life in the patients with advanced gastric cancer.